Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses and Multiple Doses of WVE-006 in Healthy Participants

NCT06186492 is registered in ClinicalTrials.gov with Wave Life Sciences USA, Inc. as lead sponsor.

NCT NCT06186492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06186492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses and Multiple Doses of WVE-006 in Healthy Participants
Lead sponsor
Wave Life Sciences USA, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 14, 2023
Completion date
February 13, 2025
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alpha-1 antitrypsin deficiency (aatd)